Vaxcyte, Inc. (PCVX)

Chimerix Statistics

Total Valuation

Vaxcyte has a market cap or net worth of $4.26 billion. The enterprise value is $2.68 billion.

Market Cap	4.26B
Enterprise Value	2.68B

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025, after market close.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Vaxcyte has 129.00 million shares outstanding. The number of shares has increased by 23.64% in one year.

Current Share Class	129.00M
Shares Outstanding	129.00M
Shares Change (YoY)	+23.64%
Shares Change (QoQ)	+0.36%
Owned by Insiders (%)	0.69%
Owned by Institutions (%)	107.25%
Float	115.93M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.33
P/TBV Ratio	1.33
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 17.70, with a Debt / Equity ratio of 0.03.

Current Ratio	17.70
Quick Ratio	17.24
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -19.66% and return on invested capital (ROIC) is -15.00%.

Return on Equity (ROE)	-19.66%
Return on Assets (ROA)	-14.53%
Return on Invested Capital (ROIC)	-15.00%
Return on Capital Employed (ROCE)	-19.38%
Revenue Per Employee	n/a
Profits Per Employee	-$1.23M
Employee Count	414
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -58.14% in the last 52 weeks. The beta is 1.21, so Vaxcyte's price volatility has been higher than the market average.

Beta (5Y)	1.21
52-Week Price Change	-58.14%
50-Day Moving Average	34.47
200-Day Moving Average	64.91
Relative Strength Index (RSI)	39.79
Average Volume (20 Days)	1,223,110

Short Selling Information

The latest short interest is 13.62 million, so 10.56% of the outstanding shares have been sold short.

Short Interest	13.62M
Short Previous Month	14.07M
Short % of Shares Out	10.56%
Short % of Float	11.75%
Short Ratio (days to cover)	8.74

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-635.87M
Pretax Income	-497.19M
Net Income	-509.63M
EBITDA	-626.91M
EBIT	-635.87M
Earnings Per Share (EPS)	-$3.98

Balance Sheet

The company has $1.67 billion in cash and $87.21 million in debt, giving a net cash position of $1.58 billion or $12.28 per share.

Cash & Cash Equivalents	1.67B
Total Debt	87.21M
Net Cash	1.58B
Net Cash Per Share	$12.28
Equity (Book Value)	3.20B
Book Value Per Share	24.82
Working Capital	1.62B

Cash Flow

In the last 12 months, operating cash flow was -$459.78 million and capital expenditures -$133.84 million, giving a free cash flow of -$593.62 million.

Operating Cash Flow	-459.78M
Capital Expenditures	-133.84M
Free Cash Flow	-593.62M
FCF Per Share	-$4.60

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Vaxcyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-23.64%
Shareholder Yield	-23.64%
Earnings Yield	-11.96%
FCF Yield	-13.94%

Analyst Forecast

The average price target for Vaxcyte is $136.50, which is 313.39% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$136.50
Price Target Difference	313.39%
Analyst Consensus	Strong Buy
Analyst Count	10
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2